¿Cómo se comparó el EPS reciente de MPHSF con las expectativas?
¿Cómo fue el desempeño de los ingresos de Memphasys Limited MPHSF en el último trimestre?
¿Cuál es la estimación de ingresos para Memphasys Limited?
¿Cuál es la puntuación de calidad de ganancias de Memphasys Limited?
¿Cuándo informa Memphasys Limited sus ganancias?
¿Cuáles son las ganancias esperadas de Memphasys Limited?
¿Superó Memphasys Limited las expectativas de ganancias?
Estadísticas clave
Cierre Anterior
--
Precio de apertura
--
Rango del día
-
Rango de 52 semanas
-
Volumen
--
Volumen promedio
--
EPS (TTM)
--
Rendimiento de dividendos
--
Cap. de mercado
--
¿Qué es MPHSF?
Memphasys Ltd. is a life sciences company, which engages in the development and commercialization of novel reproduction and fertility solutions for humans and animals. The company is headquartered in Homebush West, New South Wales. The company went IPO on 2007-05-14. The firm is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The firm's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.